NCT03091725 (FGB) is a NA clinical trial of Roux-en-Y gastric bypass surgery in Obesity, sponsored by Washington University School of Medicine.

Who is sponsoring NCT03091725?

NCT03091725 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT03091725?

Interventions in NCT03091725: Roux-en-Y gastric bypass surgery, Low-calorie diet.

Is NCT03091725 still recruiting?

NCT03091725 is currently active, enrolled. Last updated 12 March 2026.

Last reviewed 2026-03-12 · How we verify

NCT03091725: FGB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postprandial Nutrient Homeostasis Before and After Weight Loss Induced by Low-calorie Diet or RYGB

Active, enrolled NA Last updated 12 March 2026

What this trial tests

NA trial testing Roux-en-Y gastric bypass surgery in Obesity in 30 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

25 April 2017

Primary endpoint
1 July 2026

1 December 2026

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	30
Start date	25 April 2017
Primary completion	1 July 2026
Estimated completion	1 December 2026
Sites	1 location across United States

Drugs / interventions tested

Roux-en-Y gastric bypass surgery
Low-calorie diet

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Washington University School of Medicine

Who can join

Adults 25 to 65, any sex, with Obesity. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Postprandial plasma insulin kinetics
Time frame: Baseline only (cross-sectional comparison of metabolic responses in African American and non-Hispanic White adults with obesity)
Plasma insulin kinetics will be assessed in blood samples collected before and after consuming a standard-carbohydrate or a low-carbohydrate meal.
Postprandial plasma insulin kinetics
Time frame: After 16-18% weight loss induced by LCD or RYGB (~4-6 months)
Plasma insulin kinetics will be assessed in blood samples collected before and after consuming a standard-carbohydrate or a low-carbohydrate meal.

Sponsor's own description

The purpose of this study is to compare the metabolic responses to low-carbohydrate and standard-carbohydrate meals in African Americans and non-Hispanic White adults with obesity and the effect of weight loss induced by low-calorie diet (LCD) or Roux-en-Y gastric bypass (RYGB) on the metabolic responses to low-carbohydrate and standard meals. Participants will consume: 1) a standard-carbohydrate meal (\~49 g glucose) and 2) a low-carbohydrate (\~3.4 g glucose) meal on separate study visits performed in a randomized order. We will evaluate the meals' effect before and after \~16-18% weight loss on postprandial i) insulin kinetics, ii) glucose kinetics iii) β-cell function; iv) plasma triglyceride and non-esterified fatty acid concentrations; v) plasma hormone concentrations; vi) plasma cytokine concentrations; vi) plasma metabolomics; and vii) adipose tissue transcriptomics.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Control of lipolysis by a population of oxytocinergic sympathetic neurons.
Li E, Wang L, Wang D, Chi J, et al · · 2024 · cited 34× · PMID 38093006 · DOI 10.1038/s41586-023-06830-x

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03091725 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 12 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03091725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing